|
|
|
Volumn 26, Issue 1 SUPPL. 2, 1999, Pages 112-116
|
|
Overcoming bcl-2- and p53-mediated resistance in prostate cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANDROGEN;
INTERFERON;
ISOTRETINOIN;
PACLITAXEL;
PROSTATE SPECIFIC ANTIGEN;
PROTEIN BCL 2;
PROTEIN P53;
TAXANE DERIVATIVE;
TRANSFORMING GROWTH FACTOR BETA;
ANTINEOPLASTIC ACTIVITY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER HORMONE THERAPY;
CANCER RECURRENCE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONFERENCE PAPER;
DOSE RESPONSE;
DRUG CYTOTOXICITY;
DRUG POTENTIATION;
GENE INACTIVATION;
GENE MUTATION;
GENE OVEREXPRESSION;
HUMAN;
HUMAN CELL;
MALE;
ONCOGENE;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROTEIN PHOSPHORYLATION;
TUMOR SUPPRESSOR GENE;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
DRUG RESISTANCE, NEOPLASM;
GENE EXPRESSION;
GENES, BCL-2;
GENES, P53;
HUMANS;
INTERFERONS;
MALE;
MUTATION;
PACLITAXEL;
PROSTATIC NEOPLASMS;
TRETINOIN;
|
|
EID: 0032998309
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (62)
|
|
References (30)
|
